Facebook
Twitter
LinkedIn
ForwardPractical Management of Metastatic Prostate Cancer: Guidelines and Beyond Webcast (2017): Session III
Urologists continue to indicate one of the greatest educational needs in treating CRPC patients is the sequencing of agents. With the numerous new treatments now available to urologists to manage the CRPC patient, sequencing and managing the side effects of each treatment have become increasingly important. In addition, studies are demonstrating that earlier treatment with these systemic agents has improved efficacy. Urologists play a central role in the management of metastatic and castrate resistant prostate cancer and as their role continues to increase, knowledge of the various side effects of the numerous treatments that are available is paramount.
This course will provide essential information on the role of systemic therapy in the treatment of metastatic prostate cancer, focusing upon a thorough review of the AUA CRPC Guidelines, followed by management of castrate sensitive prostate cancer with systemic agents, sequencing of agents, managing side effects of treatments, management of comorbid conditions, and identifying potential interactions between agents. Additionally, the course will include a section on pain management and training on counseling/support of patients in end-of-life issues.
Target Audience
All providers who are involved in the care of CRPC, including:
- Urologists
- Medical oncologists
- Radiation oncologists
- Advanced practice providers (e.g. ARNP, PA)
- Nursing staff.
Learning Objectives
After attending this course, participants will be able to:
- Apply the AUA CRPC Guidelines for FDA approved agents in the management of CRPC and optimization of the AUA algorithm for patient clinical benefit.
- Evaluate and diagnose CRPC patients and discuss the sequencing and combinatorial treatment strategies from both clinical and administrative perspectives.
- Analyze the role of systemic agents in androgen sensitive metastatic prostate cancer.
- Examine the side effect profiles and potential interactions of various therapeutic strategies for CRPC.
- Oversee comorbid conditions and describe their management in the context of CRPC treatment.
- Manage both the acute and chronic pain that is inherent in the care of CRPC patients.
- Communicate the pertinent end-of-life issues that surround CRPC patients and their families.
Faculty Disclosures
Course Director:
Adam S. Kibel, MD: Sanofi-Aventis: Consultant or Advisor,Scientific Study or Trial; Genomic Health: Consultant or Advisor; MTG: Consultant or Advisor; Profound: Consultant or Advisor; Dendreon: Consultant or Advisor
Course Faculty:
Tanya B. Dorff, MD: Bayer: Meeting Participant or Lecturer, Scientific Study or Trial; Janssen: Consultatnt or Advisor; Exelixis: Meeting Participant or Lecturer; EMD Serono: Meeting Participant or Lecturer; Pfizer: Consultant or Advisor, Meeting Participant or Lecturer; Eisai: Consultant or Advisor
Evan Y. Yu: Agensys: Consultant or Advisor, Scientific Study or Trial; Genentech: Meeting Participant or Lecturer, Scientific Study or Trial; Bayer: Scientific Study or Trial, Consultant or Advisor; Merck: Scientific Study or Trial; Astellas: Consultant or Advisor, Scientific Study or Trial; Janssen: Consultant or Advisor; Merck: Consultant or Advisor; Voluntis: Consultant or Advisor
Robert E. Reiter, MD: Nothing to disclose
Lawrence I. Karsh, MD: Astellas: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Dendreon: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Bayer: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Janssen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Medivation: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Genomic Health: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Myriad: Consultant or Advisor, Scientific Study or Trial; Swan Valley Medical: Consultant or Advisor, Investment Interest; Amgen: Scientific Study or Trial; Heat Biologics: Scientific Study or Trial; Bavaria Nordic Immunotherapy: Consultant or Advisor, Scientific Study or Trial; MDxHealth: Scientific Study or Trial; Lawrence Karsh: Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial, Investment Interest; Spectrum Pharmaceuticals: Consultant or Advisor, Scientific Study or Trial; FKD: Scientific Study or Trial; Pfizer: Consultant or Advisor; Sanofi: Consultant or Advisor; Tolmar: Consultant or Advisor; Ferring: Consultant or Advisor; Abbvie: Consultant or Advisor; Argos: Consultant or Advisor, Scientific Study or Trial; Astra-Zeneca: Consultant or Advisor; Augmenix: Consultant or Advisor, Scientific Study or Trial; Precision Biopsy: Consultant or Advisor, Scientific Study or Trial; Takeda: Consultant or Advisor, Scientific Study or Trial; Tokai: Consultant or Advisor, Scientific Study or Trial; 3D Biopsy: Consultant or Advisor, Scientific Study or Trial; GenomeDx Biosciences: Consultant or Advisor, Scientific Study or Trial; Precision Med: Scientific Study or Trial
Edouard J. Trabulsi, MD: GenomeDx: Consultant or Advisor
Planner Disclosures
Education Council
Timothy Charles Brand, M.D.: Nothing to disclose
Anthony A. Caldamone MD: Nothing to disclose
Peter Robert Carroll, MD, MPH: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; AUA Update: Leadership Position; Genomic Health: Scientific Study or Trial
Matthew S. Christman MD: Nothing to disclose
Jody Donaldson: Nothing to disclose
Shelby Englert: Nothing to disclose
Matthew Thomas Gettman, M.D.: COVR Medical: Consultant or Advisor; Intuitive Surgical: Consultant or Advisor; Exact Sciences: Scientific Study or Trial
Inderbir Singh Gill ,MD, M.Ch.: Nothing to disclose
Howard B. Goldman, MD: allergan: Consultant or Advisor; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Cook: Scientific Study or Trial; Nuvectra: Consultant or Advisor; Axonics: Consultant or Advisor; NewUeo: Consultant or Advisor
William C. Huang, MD: Photocure: Scientific Study or Trial; Karl Storz: Scientific Study or Trial
William C. Hulbert Jr. MD: Nothing to disclose
Brant Inman, M.D., MS, FRCSC: Dendreon: Scientific Study or Trial; Abbott Laboratories: Scientific Study or Trial; Genentech Inc: Scientific Study or Trial; Combat Medical: Consultant or Advisor, Scientific Study or Trial; FKD Therapies: Scientific Study or Trial; AstraZeneca: Consultant or Advisor; BioCancell: Consultant or Advisor; Nucleix: Scientific Study or Trial; Urogen: Scientific Study or Trial
Mark L. Jordan MD,FACS: Nothing to disclose
Hari K. Koul, MSC,PHD: Novartis Pharmaceuticals: Consultant or Advisor; Urologic Research: Leadership Position; PLOS one: Leadership Position; OMICS group: Leadership Position; Open Access Publishing: Leadership Position, Health Publishing
Martin A. Koyle MD: Nothing to disclose
Yair Lotan ,MD: abbott: Scientific Study or Trial; Cepheid: Consultant or Advisor, Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial; MDxHealth: Consultant or Advisor, Scientific Study or Trial; biocancell: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; GenomeDx Biosciences Inc: Scientific Study or Trial; photocure: Consultant or Advisor, Scientific Study or Trial
Nicole Lara Miller ,MD: Boston Scientific Corporation: Consultant or Advisor, Meeting Participant or Lecturer; Practical Reviews In Urology: Health Publishing
Manoj Monga, MD, FACS: Fortec: Other
Victor William Nitti MD: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Cook Myosite: Scientific Study or Trial; Medtronic: Scientific Study or Trial
Christopher Porter, MD: Nothing to disclose
Ganesh V. Raj MD, PhD: Ptares: Owner, Product Development; C-diagnostics corp: Consultant or Advisor, Investment Interest; amgen: Meeting Participant or Lecturer; Johnson and Johnson: Consultant or Advisor, Owner, Product Development; Astellas: Meeting Participant or Lecturer; ASTELLAS: Consultant or Advisor, Meeting Participant or Lecturer; Janssen: Owner, Product Development; BAYER: Consultant or Advisor, Meeting Participant or Lecturer; SANOFI: Consultant or Advisor, Meeting Participant or Lecturer; GaudiumRx: Leadership Position, Investment Interest, Owner, Product Development; Medivation: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; EtiraRx: Leadership Position, Investment Interest, Owner, Product Development
Jay D. Raman, MD: American Kidney Stone Management: Investment Interest; Pacific Edge Biotechnology: Consultant or Advisor, Scientific Study or Trial
Heather Schultz, NP: SUNA: Meeting Participant or Lecturer
Karl-Dietrich Sievert: AMS: Meeting Participant or Lecturer; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer; Stimguard: Meeting Participant or Lecturer, Scientific Study or Trial
Joseph A. Smith Jr.,MD: Nothing to disclose
Ryan Patrick Terlecki, MD, FACS: American Medical Systems: Consultant or Advisor, Other; Allergan: Scientific Study or Trial
Edouard John Trabulsi, MD, FACS: GenomeDx: Consultant or Advisor
Method of Participation
To claim CME credit/hours of participation for each webcast, the learner must complete to pre-test, view the webcast, complete the posttest passing with 80% accuracy and submit the evaluation.
Estimated time to complete this activity: 1.00 hours
Release Date: November, 2017
Expiration Date: November, 2020
Accreditation Statement
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The American Urological Association designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
If you have already received credit for this course by attending it or watching it live you cannot receive additional credit.
Other Learners
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
AUA Privacy and Confidentiality Policy
www.auanet.org/education/confidentiality-statement.cfm
Contact Information
American Urological Association
Office of Education
1000 Corporate Blvd.
Linthicum, MD 21090
Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800
CME Information
For all inquiries regarding CME credit email: cme@AUAnet.org
Acknowledgements
The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:
- Astellas
- AbbVie
- Genomic Health
- Sanofi Genzyme
- Tolmar Pharmaceuticals, Inc.
AUAER ensures that all educational activities are developed and implemented independent of the control and/or influence of any commercial interests (ACCME: SCS1)
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation